Respiratory disease

GrapheneDx, General Graphene Corp and Sapphiros Enter Into Strategic Partnership to Industrialize Graphene-Based Biosensors to Revolutionize Point of Care and Consumer Diagnostics

Retrieved on: 
Tuesday, June 6, 2023

GrapheneDx is an in vitro diagnostics company focused on improving diagnostic capability at the point-of-care and in consumer settings.

Key Points: 
  • GrapheneDx is an in vitro diagnostics company focused on improving diagnostic capability at the point-of-care and in consumer settings.
  • The company is an expert in functionalizing graphene to create graphene field effect transistors (GFETs), which are biosensors that can be used to detect disease in biological samples.
  • Sapphiros operates a proprietary, industry-leading reel-to-reel EVM facility for point-of-care and consumer diagnostics, with a capacity of 5 billion tests per year.
  • Combined with General Graphene's impressive scale and graphene expertise, Sapphiros will accelerate the industrialization and commercialization of GrapheneDx's biosensor technology."

GrapheneDx, General Graphene Corp and Sapphiros Enter Into Strategic Partnership to Industrialize Graphene-Based Biosensors to Revolutionize Point of Care and Consumer Diagnostics

Retrieved on: 
Tuesday, June 6, 2023

GrapheneDx is an in vitro diagnostics company focused on improving diagnostic capability at the point-of-care and in consumer settings.

Key Points: 
  • GrapheneDx is an in vitro diagnostics company focused on improving diagnostic capability at the point-of-care and in consumer settings.
  • The company is an expert in functionalizing graphene to create graphene field effect transistors (GFETs), which are biosensors that can be used to detect disease in biological samples.
  • Sapphiros operates a proprietary, industry-leading reel-to-reel EVM facility for point-of-care and consumer diagnostics, with a capacity of 5 billion tests per year.
  • Combined with General Graphene's impressive scale and graphene expertise, Sapphiros will accelerate the industrialization and commercialization of GrapheneDx's biosensor technology."

Medical Oxygen Concentrators Global Market Report 2023: Increasing Prevalence of COPD Bolsters Growth - ResearchAndMarkets.com

Retrieved on: 
Thursday, June 1, 2023

The global medical oxygen concentrators market is expected to reach USD 13.9 billion by 2030, expanding at a CAGR of 6.3% from 2023 to 2030.

Key Points: 
  • The global medical oxygen concentrators market is expected to reach USD 13.9 billion by 2030, expanding at a CAGR of 6.3% from 2023 to 2030.
  • Prevalence of respiratory disease, such as chronic bronchitis, asthma, perinatal hypoxia, and neonatal oxygen deprivation, is driving adoption of oxygen concentrators, and thereby driving the market growth.
  • Thus, increasing demand for oxygen concentrators from COPD patients is estimated to drive market growth.
  • Chapter 3 Global Medical Oxygen Concentrators Market Variables, Trends, & Scope
    Chapter 4 Global Medical Oxygen Concentrators Market: Competitive Analysis
    Chapter 5 Global Medical Oxygen Concentrators Market: Product Type Estimates & Trend Analysis
    5.2 Global Medical Oxygen Concentrators Market: Product Type Market Share Analysis, 2021 and 2030
    5.3.1 Portable medical oxygen concentrators market estimates and forecasts, 2014 - 2030 (USD Million & Units)
    5.4.1 Fixed medical oxygen concentrators market estimates and forecasts, 2014 - 2030 (USD Million & Units)
    Chapter 6 Global Medical Oxygen Concentrators Market: Application Estimates & Trend Analysis
    6.2 Global Medical Oxygen Concentrators Market: Application Market Share Analysis
    6.3.1 Home care market estimates and forecasts, 2014 - 2030 (USD Million & Units)
    6.4.1 Non homecare market estimates and forecasts, 2014 - 2030 (USD Million & Units)
    Chapter 7 Global Medical Oxygen Concentrators Market: Technology Estimates & Trend Analysis
    7.2 Global Medical Oxygen Concentrators Market: Technology Market Share Analysis
    7.3.1 Continuous flow market estimates and forecasts, 2014 - 2030 (USD Million & Units)
    7.4.1 Pulse flow market estimates and forecasts, 2014 - 2030 (USD Million & Units)
    Chapter 8 Global Medical Oxygen Concentrators Market: Regional Estimates & Trend Analysis, By Product Type, Application and Technology

New survey shows Canadians want Big Tobacco to pay for tobacco reduction efforts

Retrieved on: 
Monday, May 29, 2023

The Canadian Cancer Society, Canadian Lung Association and Heart & Stroke are calling for significant tobacco reduction measures to be included in a major lawsuit settlement currently under negotiation with Big Tobacco companies.

Key Points: 
  • The Canadian Cancer Society, Canadian Lung Association and Heart & Stroke are calling for significant tobacco reduction measures to be included in a major lawsuit settlement currently under negotiation with Big Tobacco companies.
  • "We are deeply concerned that the negotiations are being held behind closed doors and that tobacco companies are at the table but health organizations are not.
  • The defendants are Imperial Tobacco Canada Ltd, Rothmans, Benson & Hedges Inc, and JTI-MacDonald Corp, as well as their foreign parents.
  • "A settlement must be about forever changing tobacco industry behaviour," says Terry Dean, President and CEO, Canadian Lung Association.

Phase 2 Data from “ASTRAEUS” Trial of Mereo BioPharma’s Alvelestat in Alpha-1 Antitrypsin Deficiency-associated Lung Disease Presented at the 2023 American Thoracic Society International Conference

Retrieved on: 
Tuesday, May 23, 2023

In line with previous guidance, Mereo is continuing to explore potential partnerships to fund the Phase 3 development of alvelestat.

Key Points: 
  • In line with previous guidance, Mereo is continuing to explore potential partnerships to fund the Phase 3 development of alvelestat.
  • Headache is a known adverse event associated with alvelestat and is being addressed through dose-escalation during initiation of alvelestat treatment.
  • The secondary endpoints were the proportion of patients with NE below the limit of quantitation and PK, safety and tolerability.
  • Exploratory endpoints included rate of acute exacerbations of COPD, pulmonary function tests, St George’s Respiratory Questionnaire, inflammatory and lung damage biomarkers.

Sonde Health's Respiratory Responsive Vocal Biomarker Tool Differentiates Patients with Respiratory Conditions from Healthy Individuals

Retrieved on: 
Tuesday, May 23, 2023

Sonde Health , a health technology company committed to bringing accessible health monitoring to everyone, has revealed new research that demonstrates the ability of its respiratory responsive vocal biomarker (RRVB) machine learning model to differentiate patients with COVID-19 from healthy individuals with about 70% accuracy.

Key Points: 
  • Sonde Health , a health technology company committed to bringing accessible health monitoring to everyone, has revealed new research that demonstrates the ability of its respiratory responsive vocal biomarker (RRVB) machine learning model to differentiate patients with COVID-19 from healthy individuals with about 70% accuracy.
  • The RRVB tool had already shown strong performance in differentiating patients with asthma, chronic obstructive pulmonary disease (COPD), interstitial lung disease, and cough from healthy individuals.
  • These findings suggest the tool could help uncover respiratory conditions before symptoms arise.
  • The COVID-19 validation study tested this tool for its ability to differentiate patients with COVID-19 from healthy individuals with data collected from September 2020 through April 2021.

Medical Gases and Equipment Market to Reach $28.9 Billion, Globally, by 2032 at 7.6% CAGR: Allied Market Research

Retrieved on: 
Wednesday, May 17, 2023

PORTLAND, Ore., May 17, 2023 /PRNewswire/ -- Allied Market Research published a report, titled, "Medical Gases and Equipment Market: By Product Type (Medical Gases, and Medical Gas Equipment), By Application (Therapeutic, Diagnostics, and Others), By End User (Hospitals, Ambulatory Surgical Centers, Diagnostic and Research Laboratories, and Others): Global Opportunity Analysis and Industry Forecast, 2022-2032" According to the report, the global medical gases and equipment industry generated $14.3 billion in 2022, and is anticipated to generate $28.9 billion by 2032, witnessing a CAGR of 7.6% from 2023 to 2032.

Key Points: 
  • Due to the high demand for medical oxygen gas during COVID-19 pandemic, the medical gases and equipment market faced an excellent growth.
  • Procure Complete Report (416 Pages PDF with Insights, Charts, Tables, and Figures)
    The medical gases segment to maintain its leadership status throughout the forecast period.
  • Based on product type, the medical gases segment held the highest market share in 2022, accounting for nearly three-fourths of the global medical gases and equipment market revenue and is estimated to maintain its leadership status throughout the forecast period.
  • This is due to a rise in adoption of medical gases and increase in focus for the improvement of healthcare infrastructure.

Medical Gases and Equipment Market to Reach $28.9 Billion, Globally, by 2032 at 7.6% CAGR: Allied Market Research

Retrieved on: 
Wednesday, May 17, 2023

PORTLAND, Ore. , May 17, 2023 /PRNewswire/ -- Allied Market Research published a report, titled, "Medical Gases and Equipment Market: By Product Type (Medical Gases, and Medical Gas Equipment), By Application (Therapeutic, Diagnostics, and Others), By End User (Hospitals, Ambulatory Surgical Centers, Diagnostic and Research Laboratories, and Others): Global Opportunity Analysis and Industry Forecast, 2022-2032" According to the report, the global medical gases and equipment industry generated $14.3 billion in 2022, and is anticipated to generate $28.9 billion by 2032, witnessing a CAGR of 7.6% from 2023 to 2032.

Key Points: 
  • Due to the high demand for medical oxygen gas during COVID-19 pandemic, the medical gases and equipment market faced an excellent growth.
  • Procure Complete Report (416 Pages PDF with Insights, Charts, Tables, and Figures)
    The medical gases segment to maintain its leadership status throughout the forecast period.
  • Based on product type, the medical gases segment held the highest market share in 2022, accounting for nearly three-fourths of the global medical gases and equipment market revenue and is estimated to maintain its leadership status throughout the forecast period.
  • This is due to a rise in adoption of medical gases and increase in focus for the improvement of healthcare infrastructure.

Owlstone Medical Wins Contract from U.S. Department of Defense to Develop Handheld Breath Biopsy Device for Early Infectious Disease Detection

Retrieved on: 
Wednesday, May 17, 2023

Owlstone Medical (“Owlstone”), the global leader in Breath Biopsy® for applications in early disease detection and precision medicine, today announced that it had won an award from the U.S. Defense Innovation Unit (DIU), a division of the U.S. Department of Defense (DoD), for ‘Exhaled Breath Diagnostics’.

Key Points: 
  • Owlstone Medical (“Owlstone”), the global leader in Breath Biopsy® for applications in early disease detection and precision medicine, today announced that it had won an award from the U.S. Defense Innovation Unit (DIU), a division of the U.S. Department of Defense (DoD), for ‘Exhaled Breath Diagnostics’.
  • The ‘EXHALE’ project, focused on the early detection of human infection using volatile organic compounds (VOCs) on breath, will develop a handheld device capable of non-invasive detection of pre-symptomatic respiratory infectious disease.
  • Warfighters routinely operate in remote environments where access to medical personnel is limited and the ability to diagnose infectious disease early is challenging.
  • The portable device by Owlstone will be adapted to work off battery power and detect VOCs present in exhaled breath, filling a gap in infectious disease detection.

Co-Diagnostics, Inc. to Host Booth at Senior Living Executive Conference in New Orleans, LA

Retrieved on: 
Tuesday, May 9, 2023

The conference is the official meeting of Argentum, the leading national association exclusively dedicated to supporting companies operating professionally managed, resident-centered senior living, and is described as an opportunity to connect with thousands of executives and experts in the senior living space, with over 750 exhibiting companies and thousands of participants.

Key Points: 
  • The conference is the official meeting of Argentum, the leading national association exclusively dedicated to supporting companies operating professionally managed, resident-centered senior living, and is described as an opportunity to connect with thousands of executives and experts in the senior living space, with over 750 exhibiting companies and thousands of participants.
  • The Company's booth will showcase Co-Diagnostics' upcoming Co-Dx PCR Home™ testing platform and its planned pipeline of respiratory disease diagnostics, including COVID-19, influenza, RSV and tuberculosis.
  • More information about the conference may be found here .
  • Attendees interested in learning more about the Company and its upcoming Co-Dx PCR Home platform, which is subject to FDA review and is not available for sale, are invited to visit the Company's booth.